Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world

作者
Jin-Kai Feng,Zong‐Han Liu,Zhigang Fu,Zong‐Tao Chai,Juxian Sun,Kang Wang,Yuqiang Cheng,Hongfei Zhu,Yan‐Jun Xiang,Liping Zhou,Jie Shi,Wei‐Xing Guo,Jian Zhai,Shuqun Cheng
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:12: 954203-954203 被引量:17
标识
DOI:10.3389/fonc.2022.954203
摘要

Purpose: This study aimed to assess the efficacy and safety of a triple therapy that comprises transarterial chemoembolization (TACE), antiangiogenic-targeted therapy, and programmed death-1 (PD-1) inhibitors in a real-world cohort of patients with unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Methods: Consecutive patients treated with TACE combined with antiangiogenic therapy and PD-1 inhibitors at the Eastern Hepatobiliary Surgery Hospital between June 2019 and May 2021 were enrolled. The baseline characteristics and treatment course of the patients were recorded. The tumor response was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and HCC-specific modified RECIST (mRECIST). The overall survival (OS) and progression-free survival (PFS) of the patients were analyzed using the Kaplan-Meier method. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Results: As of the data cutoff on 30 August 2021, the median follow-up time was 10.0 (3.9-28.4) months. A total of 39 eligible patients were included. The objective response rate (ORR) and the disease control rate (DCR) were 35.9% and 74.4% according to the RECIST 1.1, and 48.7% and 84.6% according to mRECIST criteria, respectively. The median OS and PFS were 14.0 and 9.2 months, respectively. Moreover, 34 (87.2%) patients experienced at least one treatment-related AE and 8 (20.5%) patients experienced grade 3/4 treatment-related AEs. The most common treatment- and laboratory-related AEs were hypertension (46.2%) and decreased albumin (53.8%), respectively. No treatment-related mortality occurred during the study period. Conclusions: TACE combined with antiangiogenic-targeted therapy and immune checkpoint inhibitors may have promising anticancer activity in unresectable HCC patients with PVTT. AEs were manageable, with no unexpected overlapping toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
乐鱼发布了新的文献求助10
1秒前
英勇皮皮虾完成签到,获得积分10
1秒前
1x1ao发布了新的文献求助10
1秒前
我是老大的应助被冬瓜鑫采纳,获得10
1秒前
chenisyu完成签到,获得积分10
2秒前
斯文败类的应助被朴实的以南采纳,获得10
2秒前
LYP完成签到,获得积分10
2秒前
2秒前
2秒前
上官若男的应助被xianggua采纳,获得10
3秒前
顺利毕业发布了新的文献求助10
3秒前
3秒前
3秒前
钟梓袄发布了新的文献求助10
4秒前
4秒前
4秒前
ke完成签到,获得积分10
4秒前
Lu完成签到 ,获得积分10
4秒前
5秒前
5秒前
ZJL完成签到,获得积分10
5秒前
倒拔垂杨柳的应助被多情的仰采纳,获得10
6秒前
在水一方的应助被端庄凝天采纳,获得10
6秒前
DW的应助被ppat5012采纳,获得10
6秒前
6秒前
Leo发布了新的文献求助10
6秒前
7秒前
高大的如彤完成签到 ,获得积分10
7秒前
化学胖子发布了新的文献求助100
7秒前
7秒前
孙航航完成签到,获得积分10
7秒前
英俊的铭的应助被真的头疼捏采纳,获得10
8秒前
lyx发布了新的文献求助10
8秒前
子书秋华完成签到,获得积分10
9秒前
41发布了新的文献求助10
9秒前
10秒前
绝版肉肉完成签到,获得积分10
10秒前
ciara完成签到,获得积分10
10秒前
柠A发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124